Why are sodium channel modulators not yet pharmacotherapeutic trailblazers for neuropathic pain?

Neuropathic Pain: Mechanism-Based Therapeutics

(2020) Kirsty Bannister et al.   Annual Review of Pharmacology and Toxicology

Differential effect of lacosamide on Nav1.7 variants from responsive and non-responsive patients with small fibre neuropathy

(2020) Julie IR Labau et al.   BRAIN

Reliability and Validity of the Boston Bedside Quantitative Sensory Testing Battery for Neuropathic Pain

(2020) Alexandra E Koulouris et al.   PAIN MEDICINE

Defining the Functional Role of NaV1.7 in Human Nociception

(2019) Lucy A. McDermott et al.   NEURON

Sodium Channels in Human Pain Disorders: Genetics and Pharmacogenomics

(2019) Sulayman D. Dib-Hajj et al.   Annual Review of Neuroscience

A Novel Algorithm to Identify Predictors of Treatment Response: Tapentadol Monotherapy or Tapentadol/Pregabalin Combination Therapy in Chronic Low Back Pain?

(2019) Jan C. Otto et al.   Frontiers in Neurology

Effect of lacosamide in peripheral neuropathic pain: study protocol for a randomized, placebo-controlled, phenotype-stratified trial

(2019) Malin E. Carmland et al.   Trials

Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy

(2018) Aoibhinn McDonnell et al.   PAIN

Neuropathy following spinal nerve injury shares features with the irritable nociceptor phenotype: A back-translational study of oxcarbazepine

(2018) Ryan Patel et al.   EUROPEAN JOURNAL OF PAIN

Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial

(2018) Bianca T A de Greef et al.   BRAIN

Pain relief in a neuropathy patient by lacosamide: Proof of principle of clinical translation from patient-specific iPS cell-derived nociceptors

(2018) Barbara Namer et al.   EBioMedicine

Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial

(2017) Joanna M Zakrzewska et al.   LANCET NEUROLOGY

Peripheral neuropathic pain

(2017) Ralf Baron et al.   PAIN

Rare Nav1.7 variants associated with painful diabetic peripheral neuropathy

(2017) Iulia Blesneac et al.   PAIN

Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis

(2015) Nanna B Finnerup et al.   LANCET NEUROLOGY

Osteoarthritis-dependent changes in antinociceptive action of Nav1.7 and Nav1.8 sodium channel blockers: An in vivo electrophysiological study in the rat

(2015) W. Rahman et al.   NEUROSCIENCE

The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study

(2014) Dyveke T. Demant et al.   PAIN

Gain-of-function Nav1.8 mutations in painful neuropathy

(2012) C. G. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons

(2012) Michael S. Minett et al.   Nature Communications